A comprehensive view of BioNTech SE. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

FDA grants emergency use authorization for Pfizer-BioNTech’s and Moderna’s COVID-19 vaccines for children ages 6 months to 4 years-old; 2.5 million doses of Pfizer vaccine ordered, 1.3 million doses of Moderna vaccine ordered
Published: June 17, 2022 by Daily Montanan
Sanofi reports Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron BA.1, BA.2; company states booster has stronger immune response than Pfizer-BioNTech’s Comirnaty booster
Published: June 14, 2022 by GlobeNewswire
Pfizer and BioNTech to apply to have their COVID-19 vaccine approved for children under age 5 after clinical trial shows safety of three doses of 3-microgram formulation of the vaccine; no vaccine has yet been approved for children in this age group
Published: May 25, 2022 by CE Noticias Financieras
FDA approves Pfizer COVID-19 booster shots for healthy 5-to-11 year-old children, as CDC decides whether to approved booster; about 30% of eligible kids in 5-to-11 age group have received two doses of Pfizer vaccination
Published: May 18, 2022 by Associated Press
Atrium Health Levine Children’s Hospital in Charlotte, North Carolina, starts Pfizer-BioNTech COVID-19 vaccine study in healthy children ages six months old to under five years of age; over 350 million doses of the vaccine have been administered in US
Published: May 17, 2022 by Contify Life Science News

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count